Midwest Professional Planners LTD purchases shares in Edwards Lifesciences Co. (NYSE:EW)

Financial Planners


Midwest Professional Planners Inc. The company increased its position in the stock of Edwards Lifesciences (NYSE: EW – Get Rating) by 6.2% in the fourth quarter, according to its latest disclosure to the SEC. The fund held 25,865 shares in the medical research company after purchasing an additional 1,513 shares during the quarter. Midwest Professional Planners LTD.’s Edwards Lifesciences holdings were valued at $1,930,000 as of the latest filing with the SEC.

Other hedge funds and institutional investors have also recently bought and sold shares in the company. Sequoia Financial Advisors LLC increased his position in Edwards Life Sciences by 64.2% during the fourth quarter. Sequoia Financial Advisors LLC purchased an additional 5,247 shares last quarter and now owns 13,423 shares of the medical research company worth $1,001,000. Marble Harbor Investment Counsel LLC expanded its position in Edwards Life Sciences by 6.2% in the fourth quarter. Marble Harbor Investment Counsel LLC acquired an additional 4,255 shares during the period and now owns 73,305 shares of the medical research company, valued at $5,469,000. Connor Clark & ​​Lunn Investment Management Ltd. expanded its position in Edwards Lifesciences by 344.1% in the fourth quarter. Conor Clark & ​​Run Investment Management Limited acquired an additional 246,991 shares during the period and now owns 318,765 shares in the medical research company valued at $23,783,000. Confluence Wealth Services Inc. expanded his position in Edwards Lifesciences by 5.9% in the fourth quarter. Confluence Wealth Services Inc. acquired an additional 225 shares during the period and now owns 4,030 shares of the medical research company, valued at $301,000. Finally, Aviva PLC expanded its position in Edwards Lifesciences by 18.5% during the fourth quarter. Aviva PLC acquired an additional 54,585 shares during the period and now owns 349,496 shares in the medical research company valued at $34,832,000. 80.35% of the shares are held by institutional investors and hedge funds.

Wall Street analysts forecast growth

Many research firms have published reports on EW. 92 Resources reissued its “repeated” rating on Edwards Lifesciences stock in a research report on Thursday, May 4. Raymond James downgraded Edwards Lifesciences from an “outperform” rating to a “market performer” rating in a research report on Monday, February 6. Stifel Nikolaus raised his price target on Edwards Lifesciences from $75.00 to $87.00 in a research report on Monday, April 24. Piper Sandler raised his price target on Edwards Lifesciences from $80.00 to $83.00 in a report on Thursday, April 27. Finally, Mizuho raised its price target on Edwards Lifesciences from $85.00 to $95.00 in its report on Tuesday, April 25. One investment analyst rated the stock “sell”, 10 “hold” and eight “buy”. Based on MarketBeat.com data, Edwards Lifesciences currently has an average valuation of Hold and an average target price of $89.63.

Insider activity

In other news, Vice President Jean-Luc M. Lemercier sold 6,640 shares of Edwards Life Sciences stock in a transaction on Wednesday, March 8. The shares sold at an average price of $76.96 for a total transaction value of $511,014.40. After the transaction, the Vice President owns 168,875 shares of the company, valued at $12,996,620. The sale was disclosed in filings with the Securities and Exchange Commission, which can be accessed at this link. In other news, Vice President Jean-Luc M. Lemercier sold 6,640 shares of Edwards Life Sciences stock in a transaction on Wednesday, March 8. The shares sold at an average price of $76.96 for a total transaction value of $511,014.40. After the transaction, the Vice President owns 168,875 shares of the company, valued at $12,996,620. The sale was disclosed in filings with the Securities and Exchange Commission, which can be accessed at this link. Also, CFO Scott B. Ulem sold 80,700 shares of Edwards Lifesciences in a deal on Wednesday, May 10. The shares sold at an average price of $88.54 for a total of $7,145,178.00. After the sale, the Chief Financial Officer now directly owns 18,294 shares of the company, valued at approximately $1,619,750.76. Disclosure information regarding this sale can be found here. In the last quarter, insiders sold 182,670 shares of the company, valued at $15,691,418. 1.29% of the shares are owned by corporate insiders.

Edwards Lifesciences price performance

EW shares fell $4.20 to $84.96 during trading hours on Tuesday. The company’s average turnover was 3,172,649 shares against his 851,865 shares exchanged. The company has a market capitalization of $51.5 billion, a P/E ratio of 37.00 times, a PEG ratio of 5.00 times, and a beta of 1.02 times. The company has a debt to equity ratio of 0.10, a current ratio of 3.01 and a quick ratio of 2.17. The company’s 50-day simple moving average is $84.88 and its 200-day simple moving average is $79.26. Edwards Lifesciences hit a one-year low of $67.13 and a one-year high of $107.92.

Edwards Lifesciences (NYSE:EW – Get Rating) last released its quarterly earnings data on Wednesday, April 26. The medical research firm reported earnings per share of $0.62 for the quarter, beating consensus expectations of $0.61 by $0.01. Edwards Lifesciences’ return on equity was 25.81% and net profit margin was 27.07%. The business had sales of $1.46 billion in the quarter, compared with analyst expectations of $1.39 billion. The company’s EPS in the same period last year was $0.60. The company’s revenue increased by 8.8% compared to the same period last year. Sell-side analysts expect the group as a whole to post earnings per share of $2.55 for Edwards Lifesciences this year.

Edwards Lifesciences Company Profile

(get rating)

Edwards Lifesciences Corp. is committed to patient-centric medical innovations for cardiac and critical care monitoring. The company’s products are grouped into his four main areas: transcatheter aortic valve replacement, transcatheter mitral and tricuspid valve therapy, cardiac structural surgery, and critical care.

Featured Stories

Want to know if other hedge funds hold EW? Visit HoldingsChannel.com to get the latest 13F filings and insider trading for Edwards Lifesciences Co. (NYSE:EW – rated).

Edwards Lifesciences Quarterly Institutional Ownership (NYSE:EW)

This instant news alert was generated by MarketBeat’s narrative science technology and financial data to provide our readers with the fastest and most accurate reporting. This article was reviewed by MarketBeat’s editorial team prior to publication. Please send any questions or comments regarding this story to contact@marketbeat.com.

Listen to this before you consider Edwards Lifesciences.

MarketBeat tracks Wall Street’s highest-rated, highest-performing research analysts and the stocks they recommend to clients every day. Edwards Lifesciences wasn’t on the list after MarketBeat identified five stocks top analysts are secretly whispering to customers to buy now before the whole market goes up.

Edwards Lifesciences currently has a ‘Hold’ rating among analysts, but high-scoring analysts think these five stocks are better buys.

Click here for 5 brands

A Beginner's Guide to Retirement Stock Covers



Source link

Leave a Reply

Your email address will not be published. Required fields are marked *